NCT01379807 - Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2015

Conditions

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

panitumumab + docetaxel + cisplatino

Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.

Trial Locations (9)

15006

Complejo Hospitalario Universitario de A Coruña, A Coruña

15009

Centro Oncológico de Galícia, A Coruña

15405

Hospital Arquitecto Mercide, Ferrol

15706

Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela

27003

Hospital Universitario Lucus Augusti, Lugo

32005

Complejo Hospitalario Ourense, Ourense

36002

Hospital de Pontevedra, Pontevedra

36204

Complejo Hospitalario Universitario de Vigo (Xeral Cies), Vigo

36211

Policlínica de Vigo S.A., Vigo